MAP2K1 and lung carcinoma: Here we chose several MEK1 and MEK2 mutations including (i) the MEK1-Q56P that is known to either induce lung cancer (32), AVM (9) or resistance to MEK-inhibitors treatment of melanoma (36) as well as its MEK2 equivalent MEK2-Q60P that plays a role in resistance to MEK-inhibitors (37).